ADU-S100 clinical trials
Also written MIW815 and ADU-S100.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses ADU-S100 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Chinook Therapeutics, Inc. (formerly Aduro) (2) · Novartis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ADU-S100 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedPhase 1Novartis PharmaceuticalsNCT03172936Written as MIW815How we know
- Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck CancerTerminatedPhase 2Chinook Therapeutics, Inc. (formerly Aduro)NCT03937141Written as ADU-S100How we know
- Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedPhase 1Chinook Therapeutics, Inc. (formerly Aduro)NCT02675439Written as ADU-S100How we know
Codes
What other systems call ADU-S100 · ClinicalTrials.gg INT001983
- MeSH (NLM) C000723773ADU-S100One source NLM
- UNII (FDA) FMW9ZVF53NADU-S100Confirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723773 | ADU-S100 | One source NLM |
| UNII (FDA) | FMW9ZVF53N | ADU-S100 | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.